Novo Nordisk wins Dutch court injunction enforcing semaglutide SPC against compounded nasal spray

PUBT · 1d ago
Novo Nordisk wins Dutch court injunction enforcing semaglutide SPC against compounded nasal spray
  • Novo Nordisk won a preliminary injunction in a Dutch patent case over a compounded semaglutide nasal spray sold by Ceban Ziekenhuisfarmacie.
  • The District Court of The Hague found infringement of Novo Nordisk’s supplementary protection certificate covering semaglutide.
  • Ceban was ordered to stop sales, remove product references, disclose supply-chain details, and pay Novo Nordisk’s legal costs.
  • The ruling targets an unapproved semaglutide nasal spray; Novo Nordisk’s marketed semaglutide brands are Wegovy, Ozempic, Rybelsus.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050942OMX_____CNEWS_EN_GNW1001256220_en) on August 05, 2026, and is solely responsible for the information contained therein.